A Real-World Matched Cohort Study of the Effect of Concomitant Amiodarone or Diltiazem Administration on Apixaban Peak and Trough Concentrations.

Background: Apixaban is a substrate for p-glycoprotein and is extensively metabolized by cytochrome P450 (CYP) 3A4. There are minimal published data regarding the effect of amiodarone and diltiazem on apixaban serum concentrations.

Objective: The aim of this study was to determine the degree of elevation of apixaban concentrations resulting from amiodarone or diltiazem.

Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins.

What Is Known And Objectives: Although the apixaban Food and Drug Administration (FDA) package insert recommends dose reduction in patients administered dual strong inhibitors of p-glycoprotein (P-gp) and cytochrome P-450 (CYP) 3A4, there are limited published data regarding potential drug-drug interactions between apixaban (Eliquis) and common p-glycoprotein (P-gp) and CYP3A4 inhibitors co-administered with statins. The aim of this study was to investigate the degree of elevation relative to apixaban serum peak and trough concentration after the co-administration of amiodarone, diltiazem and statins (atorvastatin, rosuvastatin and simvastatin).

Methods: Patients prescribed apixaban 5mg twice daily for at least one week were identified from the anticoagulation clinic database and contacted for potential enrolment.

Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban.

Background: There is no established method for monitoring the anticoagulant effects of apixaban and rivaroxaban. Linear correlation between serum levels and anti-Xa activity has been shown, with r ranging from 0.88 to 0.

Evaluation of cefazolin as a surrogate marker for cefpodoxime susceptibility for urinary tract isolates.

Of the cephalosporins, cefpodoxime has the most published clinical data for the treatment of urinary tract infections. In 2014, the Clinical and Laboratory Standards Institute (CLSI) guidelines recommended that cefazolin should be used as the surrogate marker for cefpodoxime among urinary tract isolates, replacing cephalothin. This study attempted to determine how well cefazolin serves as the surrogate marker.

Correlation of cefpodoxime susceptibility with cephalothin and cefuroxime for urinary tract isolates.

This study attempted to determine whether cefuroxime was superior to cephalothin as a surrogate marker for cefpodoxime among urinary tract isolates. The MicroScan system (Siemens) was used to determine susceptibility for cephalothin and cefuroxime on consecutive cultures with a colony count of ≥50 000 organisms. Simultaneously, an Etest (bioMérieux) for cefpodoxime was conducted.

Effect of coenzyme Q10 supplementation on statin-induced myalgias.

Coenzyme Q10 (CoQ10) deficiency has been proposed to be causal in 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor (statin)-induced myopathies. However, the clinical benefit of supplementation is unproved. The purpose of the present study was to assess the effect of CoQ10 supplementation on myalgias presumed to be caused by statins.

Assessment of the white-coat effect among hypertensive patients presumed to be at goal.

Background: There are limited studies that explore the rate of existent uncontrolled hypertension versus a significant white-coat effect. Likewise, few studies have described the physician's response to the results of an ambulatory blood pressure monitoring (ABPM) study.

Objective: To determine the percentage of treated hypertensive patients referred for ABPM based on discrepant office and home blood pressures who had achieved goal blood pressure and to determine the degree of white-coat effect in these patients.